Online citations, reference lists, and bibliographies.
← Back to Search

Phase I Dose-finding And Pharmacokinetic Study Of Paclitaxel And Carboplatin With Oral Valspodar In Patients With Advanced Solid Tumors.

A. Patnaik, E. Warner, M. Michael, M. Egorin, M. Moore, L. Siu, P. Fracasso, S. Rivkin, I. Kerr, M. Litchman, A. Oza
Published 2000 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
PURPOSE To evaluate the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic (PK) profile of paclitaxel and carboplatin when administered every 3 weeks with the oral semisynthetic cyclosporine analog valspodar (PSC 833), an inhibitor of P-glycoprotein function. PATIENTS AND METHODS Fifty-eight patients were treated with escalating doses of paclitaxel ranging from 54 to 94.5 mg/m(2) and carboplatin area under the plasma concentration versus time curve (AUC) ranging from 6 to 9 mg.min/mL, every 21 days. The dose of valspodar was fixed at 5 mg/kg every 6 hours for a total of 12 doses from day 0 to day 3. The MTD was determined for the following two groups: (1) previously treated patients, where paclitaxel and carboplatin doses were escalated; and (2) chemotherapy-naïve patients, where paclitaxel dose was escalated and carboplatin AUC was fixed at 6 mg.min/mL. PK studies of paclitaxel and carboplatin were performed on day 1 of course 1. RESULTS Fifty-eight patients were treated with 186 courses of paclitaxel, carboplatin, and valspodar. Neutropenia, thrombocytopenia, and hepatic transaminase elevations were DLTs. In previously treated patients, no DLTs occurred at the first dose level (paclitaxel 54 mg/m(2) and carboplatin AUC 6 mg.min/mL). However, one of 12, two of six, two of four, four of 11, and two of five patients experienced DLTs at doses of paclitaxel (mg/m(2))/carboplatin AUC (mg.min/mL) of 67.5/6, 81/6, 94.5/6, 67. 5/7.5, and 67.5/9, respectively. In chemotherapy-naïve patients, one of 17 developed DLT at paclitaxel 81 mg/m(2) and carboplatin AUC 6 mg/mL.min. There was prolongation of the terminal phase of paclitaxel elimination as evidenced by an increased time that plasma paclitaxel concentration was >/= 0.05 micromol/L, ranging from 16.6 +/- 6.7 hours to 41.5 +/- 9.8 hours for paclitaxel doses of 54.5 mg/m(2) to 94.5 mg/m(2), respectively. CONCLUSION The recommended phase II dose in chemotherapy-naïve patients is paclitaxel 81 mg/m(2), carboplatin AUC 6 mg.min/mL, and valspodar 5 mg/kg every 6 hours. In previously treated patients, the recommended phase II dose is paclitaxel 67.5 mg/m(2), carboplatin AUC 6 mg.min/mL, and valspodar 5 mg/kg every 6 hours. The acceptable toxicity profile supports the rationale for performing disease-directed evaluations of paclitaxel, carboplatin and valspodar on the schedule evaluated in this study.
This paper references
Creatinine Clearance: Bedside Estimate
R. Jelliffe (1973)
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft Dw (1976)
A program package for simulation and parameter estimation in pharmacokinetic systems.
D. Z. D'Argenio (1979)
Phase I study of vinblastine and verapamil given by concurrent iv infusion.
A. Benson (1985)
Genetic and biochemical characterization of multidrug resistance.
J. Riordan (1985)
Multiple-drug resistance in human cancer.
I. Pastan (1987)
Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line.
P. Twentyman (1987)
Mitomycin C resistant L1210 leukemia cells: association with pleiotropic drug resistance.
R. Dorr (1987)
Expression of a multidrug-resistance gene in human tumors and tissues.
A. Fojo (1987)
The effect of insulin on steroid metabolism in isolated rat hepatocytes.
Abas Hj. Hussin (1987)
Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial.
R. L. Miller (1988)
P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD.
J. Epstein (1989)
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
W. Dalton (1989)
Expression of a multidrug resistance gene in human cancers.
L. Goldstein (1989)
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
A. Calvert (1989)
Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer.
J. Ro (1990)
Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine.
H. Herweijer (1990)
Pharmacology of drugs that alter multidrug resistance in cancer.
J. Ford (1990)
In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.
D. Bösch (1991)
Expression of the Multidrug Resistance Gene in Human Cancer
M. Gottesman (1991)
Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative.
D. Bösch (1991)
Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.
B. Lum (1992)
SDZ PSC 833, A non‐immunosuppressive cyclosporine: Its potency in overcoming P‐glycoprotein‐mediated multidrug resistance of murine leukemia
R. Keller (1992)
Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis.
L. Campos (1992)
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.
M. Huizing (1993)
Pharmacokinetics for the Pharmaceutical Scientist
J. Wagner (1993)
Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
C. Erlichman (1993)
Clinical significance of P-glycoprotein in multidrug resistance malignancies [editorial] [see comments]
R. Arceci (1993)
The pharmacokinetics and bioavailability of a new chemosensitizer, SDZ PSC 833, in patients with advanced cancer: 101
J. Thiessen (1994)
The effect of oral SDZ PSC 833 on the pharmacokinetics (PK) of etoposide (E) during a phase I trial to modulate multidrug resistance: 102
B. Lum (1994)
Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.
N. Bartlett (1994)
SDZ PSC 833 in combination with doxorubicin: a phase I and pharmacologic study in solid tumors
G. Giaccone (1994)
Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
J. Schiller (1994)
Effects of 5-fluorouracil on collagen synthesis in the developing palate of hamster.
G. Benkhaial (1994)
A phase I trial of doxorubicin (DOX) and PSC 833, a modulator of multidrug resistance (MDR): 97
C. Erlichman (1994)
Paclitaxel pharmacokinetics and pharmacodynamics.
C. Kearns (1995)
Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
T. Ohtsu (1995)
Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.
L. Gianni (1995)
Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
P. Sonneveld (1996)
Antitopoisomerase drug action and resistance.
J. Nitiss (1996)
Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.
D. Boote (1996)
Major vault protein LRP-related multidrug resistance.
M. A. Izquierdo (1996)
Molecular mechanisms of multidrug resistance in cancer chemotherapy.
K. Nooter (1996)
A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel.
Calvert Ah (1997)
Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
J. van Asperen (1997)
Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
M. Huizing (1997)
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
S. Kornblau (1997)
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.
A. Sparreboom (1997)
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.
M. Huizing (1997)
[SDZ PSC 833: a novel modulator of MDR].
A. Covelli (1997)
Availability of PSC833, a Substrate and Inhibitor of P-glycoproteins, in Various Concentrations of Serum
A. Smith (1998)
Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin.
N. Simon (1998)
The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite.
V Fischer (1998)
Dose-dependent effects of PSC 833 on its tissue distribution and on the biliary excretion of endogenous substrates in rats.
S. Song (1998)
Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.
C. Belani (1999)
The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.
J. Allen (1999)
A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen
V. R. Nannan Panday (1999)
Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL
A. Ellis (1999)
Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.
P. Fracasso (2000)

This paper is referenced by
P-glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Cancer Patients.
T. Stage (2020)
Exploring β-Tubulin Inhibitors from Plant Origin using Computational Approach.
Kanika Verma (2017)
Specifications of a continual reassessment method design for phase I trials of combined drugs.
N. Wages (2013)
Dose-Finding Designs Based on the Continual Reassessment Method
J. O'quigley (2012)
A model of competing saturable kinetic processes with application to the pharmacokinetics of the anticancer drug paclitaxel.
R. Marsh (2011)
Extended model-based designs for more complex dose-finding studies.
J. O'Quigley (2011)
23-Hydroxybetulinic acid from Pulsatilla chinensis (Bunge) Regel synergizes the antitumor activities of doxorubicin in vitro and in vivo.
Yuanting Zheng (2010)
Introduction to Drug Transporters
Louis Leung (2010)
Emergence of power laws in the pharmacokinetics of paclitaxel due to competing saturable processes.
R. Marsh (2008)
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.
C. Lhommé (2008)
Resistance To Taxanes
L. Greenberger (2006)
C76 - Place de l’échographie ganglionnaire haute-résolution pour prédire l’invasion du ganglion sentinelle dans le mélanome
C. Sibon (2005)
A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy
A. Sandler (2004)
Designs for single- or multiple-agent phase I trials.
M. Conaway (2004)
Effect of valspodar on the pharmacokinetics of unbound paclitaxel
A. T. Ten Tije (2004)
Chapter 31 – Primary Chemotherapy for Advanced Epithelial Ovarian Cancer
P. Vasey (2004)
Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans.
F. Imbert (2003)
S. Bates (2003)
P-Glycoprotein Inhibition in Acute Myeloid Leukemia
T. Chauncey (2003)
Pharmacokinetic Study of Infusional Valspodar
M. K. Ma (2002)
Overcoming drug resistance in ovarian carcinoma
P. Fracasso (2001)
A Phase I study of infusional vinblastine in combination with the p‐glycoprotein antagonist PSC 833 (valspodar)
S. Bates (2001)
Multidrug resistance transporters and modulation
B. Tan (2000)
Semantic Scholar Logo Some data provided by SemanticScholar